A Phase 2b Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs BLS-ILB-E710c (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors Bioleaders Corporation
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2018 Planned End Date changed from 31 Aug 2019 to 31 Dec 2018.
- 04 Apr 2018 Planned primary completion date changed from 30 Jun 2019 to 31 Oct 2018.